ライフサイエンスコーパス: drug screening

1 cardiac disease and serve as a test bed for drug screening.

2 nology (cancer models) for use in anticancer drug screening.

3 d with treatment outcomes profiles and urine drug screening.

4 oader context of respiratory disease and for drug screening.

5 or in vitro modeling of cardiac fibrosis and drug screening.

6 termed DNA-encoded libraries, accessible for drug screening.

7 evaporative dry-eye disease for high-content drug screening.

8 has been developed towards a high throughput drug screening.

9 for studying specific CPVT mutations and for drug screening.

10 thereby providing an excellent platform for drug screening.

11 ritical when analyzing PTPs, for example, in drug screening.

12 regenerative medicine, disease modeling, and drug screening.

13 ary development and for disease modeling and drug screening.

14 showing great potential for high-throughput drug screening.

15 s, disease diagnostics, and chemotherapeutic drug screening.

16 nmental samples, and can also be applied for drug screening.

17 the migratory capability and anti-metastatic drug screening.

18 ential to enable more physiological in vitro drug screening.

19 n native HD tissue samples and for potential drug screening.

20 the CNS to allow pharmacological testing and drug screening.

21 stem cell research, tissue engineering, and drug screening.

22 study cancer cell migration and anti-cancer drug screening.

23 lene) glycol diacrylate (PEGDA) hydrogel for drug screening.

24 e a good model for further investigation and drug screening.

25 es to perform rapid, large-scale genomic, or drug screening.

26 o use EHM for iPS-based disease modeling and drug screening.

27 ology, combinatorial chemical synthesis, and drug screening.

28 ing of anti-cancer mechanism and anti-cancer drug screening.

29 iothreat detection, clinical diagnostics and drug screening.

30 ant clones were detected with clone-specific drug screening.

31 e cannot be used for studies of TANDs or new drug screening.

32 igation of the biology of CRC metastasis and drug screening.

33 mechanistic studies of tumor biology and for drug screening.

34 platform for vascular disease modelling and drug screening.

35 ne expression profiling, and high-throughput drug screening.

36 development, as well as disease modeling and drug screening.

37 ogical application, disease diagnostics, and drug screening.

38 to have application in cellular imaging and drug screening.

39 period of abstinence and 64% requiring urine drug screening.

40 f a hEPC endothelialized hMSC-based TEBV for drug screening.

41 e study of human organogenesis, disease, and drug screening.

42 polarization form a powerful combination for drug screening.

43 uloskeletal diseases in a dish and for rapid drug screening.

44 ove the disease relevance of assays used for drug screening.

45 le for fast high throughput anti-aggregation drug screening.

46 plications such as regenerative medicine and drug screening.

47 s, can be interrogated structurally to allow drug screening.

48 a, and in cell lines through high-throughput drug screening.

49 es, examination of human-specific genes, and drug screening.

50 w beta-cells for transplantation therapy and drug screening.

51 diagnosis, protein biomarkers screening and drug screening.

52 ved hydrophobic cavity suitable for targeted drug screening.

53 turing in relation to, e.g., diagnostics and drug screening.

54 for G protein-coupled receptor (GPCR) biased drug screening.

55 tethered spheroid models to high throughput drug screening.

56 rus 2 (SARS-CoV-2) biology and to facilitate drug screening.

57 velopmental pharmacology and toxicology, and drug screening.

58 cancer research, from mechanistic studies to drug screening.

59 ere used to validate the ASYN-CONA assay for drug screening.

60 egy to enable functional genetic studies and drug screening.

61 pplications, including disease modelling and drug screening.

62 n vitro are not suitable for high-throughput drug screening.

63 actical applications in cancer diagnosis and drug screening.

64 heroids mimic the tumor microenvironment for drug screening.

65 rotein, outlining an approach for phenotypic drug screening.

66 timing for cell transplantation studies and drug screening.

67 ned cell types for restorative therapies and drug screenings.

68 Twenty-eight studies (n = 65 720) addressed drug screening accuracy.

69 evelop automated, quantitative approaches to drug screening against helminth diseases.

70 Drug screening against helminths has often been phenotyp

71 hPSCs) offer many potential applications for drug screening and 'disease in a dish' assay capabilitie

72 logy has progressed as a promising model for drug screening and aiding cancer therapy.

73 promise in disease modelling, pharmaceutical drug screening and cell therapy for Huntington's disease

74 Cs) are used as platforms for disease study, drug screening and cell-based therapy.

75 ction of kidney function in both preclinical drug screening and clinical settings.

76 l of the epidemic, and even support targeted drug screening and delivery within the integration of em

77 iagnosis, food safety, environmental health, drug screening and delivery.

78 classifying cells based on their viability, drug screening and detecting populations of malignant ce

79 toward various forms of xenograft models for drug screening and development.

80 genetic pathological factors could help with drug screening and development.

81 k in basic biology research, high-throughput drug screening and digital pathology is identifying the

82 personalized cancer medicine at early-stage drug screening and discovery.

83 used for various applications such as early drug screening and disease modeling.

84 ticipate the widespread adoption of MPSs for drug screening and disease modeling.

85 defects and establish a platform to advance drug screening and disease modeling.

86 tial for applications in precision medicine, drug screening and disease risk assessment.

87 PSCs) are essential to personalized in vitro drug screening and disease study.

88 ial cardiomyopathies as well as for in-vitro drug screening and drug discovery.

89 form will greatly facilitate high-throughput drug screening and electrophysiological characterization

90 without the use of solvents, can accelerate drug screening and enable continuous manufacturing, whil

91 LTP in AD, thus opening up a new avenue for drug screening and evaluation of strategies for alleviat

92 this powerful new set of tools for improved drug screening and for investigating early mechanisms dr

93 ngineered environments open new -avenues for drug screening and fundamental studies of wound healing,

94 ning structure-assisted drug design, virtual drug screening and high-throughput screening.

95 ation of high-quality chemical libraries for drug screening and in applications such as drug repositi

96 Future applications such as drug screening and in point of care applications are the

97 in vivo models of C. difficile infection for drug screening and lead optimization.

98 This model may provide a platform for drug screening and mechanism studies on solid tumor inte

99 y diverse human sensory neurons suitable for drug screening and mechanistic studies.

100 gs validate a unique BCSC culture system for drug screening and offer preclinical proof of concept fo

101 del can be used for studying high throughput drug screening and other pre-clinical applications.

102 atforms for ultrahigh-throughput combination drug screening and polymerase chain reaction (PCR)-based

103 aterial for therapeutic intervention such as drug screening and potentially also for cell-based thera

104 ul platform in cases such as high-throughput drug screening and prolonged drug release.

105 tiple cell derivatives provide platforms for drug screening and promising treatment options for a wid

106 nerative medicine, modeling of lung disease, drug screening and studies of human lung development.

107 nerative medicine, modeling of lung disease, drug screening and studies of human lung development.

108 ranslational pain research, and enable rapid drug screening and testing of newly engineered opsins.

109 ion kinetics for many applications including drug screening and the investigation of the mechanisms o

110 ially be used for the treatment of diabetes, drug screening and the study of beta-cell biology.

111 tential applications, including personalized drug screening and therapeutic strategies for liver fail

112 ontractile force screening system useful for drug screening and tissue engineering applications.

113 s massive hiPSC-CM expansion for large-scale drug screening and tissue engineering applications.

114 cs screening-e.g., for clinical phenotyping, drug screening and toxicity testing.

115 We find, using a combination of large-scale drug screening and whole-exome sequencing, that our erlo

116 racterised models for basic cancer research, drug-screening and personalised medicine.

117 t, therefore, be amenable to industrial (eg, drug screening) and clinical (eg, cardiac repair) applic

118 ential of a transcription-based platform for drug screening, and advance two novel lead compounds for

119 nderstanding of cancer pathology, anticancer drug screening, and cancer treatment development.

120 l to produce podocytes for disease modeling, drug screening, and cell therapies.

121 tial cell source for heart disease modeling, drug screening, and cell-based therapeutic applications.

122 ker discovery, molecular interaction assays, drug screening, and clinical diagnostics.

123 f applications such as inflammation studies, drug screening, and coculture interactions.

124 Tissue engineering, gene therapy, drug screening, and emerging regenerative medicine thera

125 llenge for applications in disease modeling, drug screening, and heart repair.

126 mplications in functional molecular studies, drug screening, and iPS cell-based platforms for disease

127 ould have broad utility in disease modeling, drug screening, and regenerative medicine.

128 e for their application in disease modeling, drug screening, and regenerative medicine.

129 using iPSC technology for disease modeling, drug screening, and the development of stem cell therape

130 re unlikely to be found through conventional drug screening, and they include kinase inhibitors and d

131 be used for investigating tumor biomarkers, drug screening, and understanding tumor progression and

132 parasites suitable for in vitro and in vivo drug screening, and we evaluated the basis of drug susce

133 fmol, which would be a useful attribute for drug screening applications or testing of small quantiti

134 Particularly for drug screening applications, high-temporal resolution ce

135 underscoring the potential of the system for drug screening applications.

136 ug formulations and might also be useful for drug screening applications.

137 s very attractive for tissue engineering and drug screening applications.

138 yte detection and is particularly suited for drug screening applications.

139 We thus performed a drug screening approach using a library consisting of ep

140 des a powerful tool for disease modeling and drug screening approaches.

141 The basis of the next generation of drug-screening approaches is set to be in silico risk pr

142 d by topoisomerase inhibitors in an oncology drug screening array and altered variant composition of

143 could serve as a valuable system to expedite drug screening as well as to study intestinal transporte

144 which can potentially be used for in silico drug screening, as well as contributing to understanding

145 ritable neurological disorders, and advances drug screening, as well as personalized medicine.

146 ystem as an alpha-synuclein anti-aggregating drug screening assay a panel of 10 drugs was tested.

147 cal proteomics and an organotypic cell-based drug screening assay, we determine the functional role o

148 nal multi-assay algorithm and antiretroviral drug screening assay.

149 limit of 10 pg/ml, as well as demonstrated a drug screening assay.

150 Using a cell-based drug-screening assay, we identified Acriflavine (ACF), a

151 Through a series of further drug screening assays and two-drug combination testing,

152 Fluorescent drug screening assays are essential for tyrosine kinase

153 New reliable and cost-effective antimalarial drug screening assays are urgently needed to identify dr

154 Drug screening assays identified a compound targeting th

155 We show that OC organoids can be used for drug-screening assays and capture different tumor subtyp

156 enerative diseases and in proof-of-principle drug-screening assays.

157 l microarray imaging approach for anticancer drug screening at specific cancer protein-protein interf

158 lytes, immunoassays, gene expression assays, drug screening, bioimaging of live organisms, cancer stu

159 s demonstrate the potential utility of rapid drug screening combined with genomic profiling for preci

160 sing a panel of AMD biomarkers and candidate drug screening, combined with transcriptome analysis, we

161 Next generation drug screening could benefit greatly from in vivo studie

162 al genes is tested in silico using shRNA and drug screening data from cancer cell line databases.

163 an algorithm that integrates high-throughput drug screening data, comprehensive kinase inhibition dat

164 blicly available, high-quality DNA, RNA, and drug screening data.

165 on data linked to high-quality DNA, RNA, and drug-screening data have not been available across a lar

166 ration of transcriptome-profiling, published drug-screening data, and functional in vitro and in vivo

167 cally available genomic, transcriptomic, and drug-screening data.

168 ng framework is tested on benchmark in vitro drug screening datasets.

169 For example, drug screening demonstrated that actinomycin D, which is

170 nal applications of those approaches include drug screening, development of novel molecular therapies

171 of organ-on-a-chip systems, high-throughput drug screening devices, and in regenerative medicine.

172 potential for future applications including drug screening, diagnostic applications and functional a

173 ssues offer enormous potential as models for drug screening, disease modeling, and regenerative medic

174 recapitulate human responses are needed for drug screening, disease modeling, and, ultimately, kidne

175 many potential applications in modeling and drug screening for airway diseases.

176 We describe a new approach to proteome-wide drug screening for detection of on- and off-target bindi

177 tool for basic discovery and high-throughput drug screening for G-protein-coupled receptors and ion c

178 feasibility of fast and accurate anti-viral drug screening for inhibitors of SARS-CoV-2 and provides

179 d to be useful for regenerative medicine and drug screening for liver diseases.

180 e used as an indicator of cellular noise and drug screening for noise control.

181 en developed and validated in the context of drug screening for schistosomiasis, one of the most impo

182 sing cellular tool to facilitate therapeutic drug screening for severe neurodevelopmental disorders.

183 in vivo tool for high-throughput therapeutic drug screening for the improvement of muscle phenotypes

184 enes which can be used for disease modeling, drug screening, gene correction and future in vivo appli

185 hnologies are urgently required for reliable drug screening given a worldwide epidemic of prescriptio

186 Our drug screening has identified the source of the SPR peri

187 of this biosensor in future high throughput drug screening has the important potential to help ident

188 ity of BAs in a platform for high-throughput drug screening (HTS).

189 High-throughput drug screening identified small molecule inhibitors that

190 These findings show that high-throughput drug screening identifies therapies for medulloblastoma

191 ate this microfluidic device will facilitate drug screening in a relevant microenvironment thanks to

192 tform for genotype-phenotype correlation and drug screening in any human myelin disorder.

193 pigenetic biomarkers through high-throughput drug screening in approximately 1,000 molecularly annota

194 heterotypic cell-cell interactions and novel drug screening in diseased human brain.

195 is reporter-based assay allows for antiviral drug screening in human cell culture at biosafety level

196 ptimized reporter assay allows for antiviral drug screening in human cell culture at biosafety level

197 Our work lays the groundwork for label-free drug screening in pharmaceutical science and industry.

198 logical mechanisms of disease and performing drug screening in the presence of applied mechanical loa

199 to antihypertensive treatment at 6 months by drug screening in urine/plasma samples from 85 patients.

200 systematically by combinatorial CRISPR, drug-drug screening in vitro, and patient-derived xenografts.

201 Cell-based drug screenings indicate that tumors displaying c-MET ge

202 omimetic assays for interaction analysis and drug screening involving membrane components.

203 The utility of the metastatic models for drug screening is demonstrated by evaluating the antican

204 The applicability for drug screening is demonstrated by studying the effects o

205 Drug screening is facilitated by the incorporation of a

206 opment of a biomimetic 3D culture system for drug screening is necessary to fully understand the in v

207 Large-scale drug screening is needed to identify compounds with anti

208 need for a liver-on-a-chip tissue model for drug screening is particularly important in tissue engin

209 by a complete cell-based assay for efficient drug screening is performed showing a clear correlation

210 ors may be obscured by a ceiling effect when drug screening is performed under strongly phosphorylati

211 High-throughput drug screening is the standard approach to study the dru

212 such as photodynamic therapy for accelerated drug screening, magnetically guided controlled drug deli

213 ons, we developed an efficient combinatorial drug screening method called the Feedback System Control

214 Advances in high-throughput drug screening methods for small molecules, developments

215 Here, by using in silico drug-screening methods, we discovered that Celastrol, a

216 sely, we integrated a 3D-bioprinted perfused drug screening microfluidics platform.

217 inatorial printing, high-throughput parallel drug screening, modular disposable cartridge, and biocom

218 ghlight the PM as a high-fidelity target for drug screening of Kv channels.

219 However, high-throughput drug screening of P450s is limited by poor protein stabi

220 sease subset, we performed medium-throughput drug screening on CEBPA/CSF3R mutant leukemia cells and

221 onstrate the applicability of our method for drug screening on dried blood spots showing excellent li

222 s and should be valuable for high-throughput drug screening or biointeraction studies.

223 dicting and providing meaningful preclinical drug screening outcomes.

224 , as a result, lead to new clinical care and drug screening paradigms, are discussed.

225 s demonstrate the efficacy of our model as a drug screening platform and a promising tool to investig

226 A new study developed a drug screening platform utilizing human beige adipose ti

227 underlying disease mechanisms and for use as drug screening platform, particularly for reagents desig

228 ting the potential utility of our model as a drug screening platform.

229 metry imaging with PBCs (MALDI-MSI-PBC) as a drug screening platform.

230 We validate our model as a drug-screening platform by identifying several compounds

231 omatography- mass spectrometry (LC-MS) based drug-screening platform we show that Metformin, a widely

232 Innovative drug screening platforms should improve the discovery of

233 f human intestinal disease and in developing drug-screening platforms that more accurately represent

234 Proof of principle that the gene panel shows drug screening potential was obtained using a well-estab

235 l generic analytical applications, including drug screening, prion strain discrimination, biohazard s

236 as a rapid and reliable in vitro method for drug screening prior to in vivo testing.

237 A simple and cost-effective two-tier drug screening procedure comprises a 'dedicated' NIR spe

238 A hybrid drug screening procedure was proposed and applied to ide

239 itro systems have significantly advanced the drug screening process as 3D tissue models can closely m

240 re modeling and significantly accelerate the drug screening process of macromolecule-ligand complexes

241 tforms demonstrated a higher efficacy in the drug-screening process: due to the liquid folding a high

242 h can have a myriad array of applications in drug screening, programmable tissue engineering, drug de

243 stic studies of homologous recombination and drug screening programs.

244 tify all possible states and utilize them in drug screening programs.

245 ifferentiation into lineages for large-scale drug-screening programs and clinical use.

246 udy, we established a robust high-throughput drug screening protocol by using a recombinant RSV repor

247 bility of cells cultured in microsystems for drug screening purposes is usually tested with a variety

248 SM or CSPalpha aggregation as biomarkers for drug screening purposes.

249 nd versatile method which can be applied for drug-screening purposes, allowing the determination of e

250 inal cells for regenerative medicine and for drug-screening purposes, as well as an in vitro model of

251 mation from the descriptions of over 100,000 drug screening-related assays in rats and mice.

252 High-throughput drug screening revealed that bromodomain and extra-termi

253 ntegrated RNA sequencing and high-throughput drug screening revealed that the Aurora A kinase (Aurora

254 Drug screening reveals Hsp70 and MEK inhibitor combinati

255 y engraft in recipient mice, and preliminary drug screening reveals mutation-specific vulnerabilities

256 Targeted drug screening reveals that SCLC with high MYC expressio

257 s, and thus, their implementation during the drug screening stage has the potential to more accuratel

258 nt in vitro models of muscle dystrophies and drug screening strategies, as well as providing a source

259 Using this model, we designed a drug screening strategy based on the pupal lethality phe

260 ine to support feasibility of this novel TDS drug-screening strategy.

261 Drug screening studies for inflammatory skin diseases ar

262 Drug screening studies typically involve assaying the se

263 uired make zebrafish the model of choice for drug screening studies, when a valid disease model is av

264 nsplant platform amenable to high-throughput drug screening studies, yet animals eventually reject tu

265 potential in other clinical applications and drug-screening studies.

266 ntegrative bioinformatic and high throughput drug screening study to define the role of E2F2 in maint

267 This exploratory drug-screening study identified several potential target

268 In the future, iMPCCs could prove useful for drug screening, studying molecular mechanisms underlying

269 biomolecules can yield useful platforms for drug screening, synthetic biology applications, diagnost

270 behavior-based, automated, and quantitative drug screening system using this dnc-1 KD model together

271 )F NMR in establishing a conformation-guided drug screening system, advancing the cell- and structure

272 d on MOCOS expression, and paves the way for drug screening targeting MOCOS and/or the purine metabol

273 re amenable for biomarker identification and drug-screening testing and led to the identification of

274 reliable mechanistic studies and preclinical drug screenings that may eventually accelerate the drug

275 Applied to promyelination drug screening, the method uniquely enabled the identifi

276 ise for advancing precision medicine through drug screening, though it remains unclear to what extent

277 ity of this organism for large-scale in vivo drug screening, thus providing unprecedented opportuniti

278 ation of specific cardiac subpopulations for drug screening, tissue engineering, and disease modeling

279 cific cardiomyocytes, which are critical for drug screening, tissue engineering, and disease modeling

280 s rapid disease modeling and high-throughput drug screening to alleviate astrocyte-derived toxicity.

281 cations ranging from medical diagnostics and drug screening to chemical and biological warfare detect

282 nfection and provide a valuable resource for drug screening to identify candidate COVID-19 therapeuti

283 -germline neurofibroma model for preclinical drug screening to identify effective therapies.

284 , and develop platforms for, high-throughput drug screening to identify novel compounds to prevent an

285 e system to expand CSCs ex vivo for targeted drug screening, to identify promising novel treatments w

286 Cell culture assays for therapeutic drug screening today are fully automated.

287 N transcription, thus making it an efficient drug screening tool that can be used for therapeutic int

288 seful for mechanical injury studies and as a drug screening tool, and it could serve as a foundation

289 llmarks of tissue-based bioassays, including drug screening, tumor dissemination, cell co-culture, an

290 Through a proof-of-principle drug screening using BICA, we found that danusertib, an

291 ies of putative new drugs through systematic drug screening using large chemical libraries provide ho

292 his system's biotechnological application in drug screening was successfully demonstrated by the N-ox

293 Using RNA sequencing and drug screening, we find that treatment of FLT3 internal

294 Using in vitro drug screening, we identified 211 amino-acid substitutio

295 Through a series of data analysis and drug screening, we identified two compounds (i.e., NSC-3

296 al ligand-binding approach for antipsychotic drug screening where competitive binding of a novel APD

297 ve the efficacy and accuracy of OCT in vitro drug screening will greatly contribute to the field of c

298 opens a new avenue to early diagnostics and drug screening with high sensitivity.

299 We tested various models for STN drug screening with the aim of identifying the most effe

300 of protein translocation and for inhibitor (drug) screening, with an intensity and rigor unattainabl